REMEGEN(09995),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09995 REMEGEN

Not Yet Opened 01-16 16:08:25

97.800

+3.550

+3.77%

High99.250	Low94.850	Vol4.18M
Open95.400	D1 Closing94.250	Amplitude4.67%
Mkt Cap55.12B	Tradable Cap20.40B	Total Shares563.61M
T/O405.99M	T/O Rate2.00%	Tradable Shares208.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"REMEGEN","latestPrice":97.8,"timestamp":1768550905013,"preClose":94.25,"halted":0,"volume":4175542,"delay":0,"changeRate":0.03766578249336867,"floatShares":208581239,"shares":563608243,"eps":-2.73,"marketStatus":"Not Yet Opened","change":3.55,"latestTime":"01-16 16:08:25","open":95.4,"high":99.25,"low":94.85,"amount":405992739,"amplitude":0.046684,"askPrice":97.85,"askSize":3000,"bidPrice":97.8,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":-1.907353,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768786200000},"marketStatusCode":0,"adr":0,"listingDate":1604851200000,"exchange":"SEHK","adjPreClose":94.25,"openAndCloseTimeList":[[1768527000000,1768536000000],[1768539600000,1768550400000]],"volumeRatio":0.5090362876452759,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"Remegen Co.,Ltd.","latestPrice":107.25,"timestamp":1768546800000,"preClose":104.9,"halted":0,"volume":9442100,"delay":0,"premium":"-18.62"}},"requestUrl":"/m/hq/s/09995","defaultTab":"news","newsList":[{"id":"2603295991","title":"RemeGen Lifts Price Cap on Share Repurchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2603295991","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603295991?lang=en_us&edition=fundamental","pubTime":"2026-01-16 12:10","pubTimestamp":1768536623,"startTime":"0","endTime":"0","summary":"RemeGen  said it was lifting the price cap on the repurchase of its shares from the open market, according to a Hong Kong bourse filing Thursday.Shares of the biopharmaceutical research company gained nearly 3% in morning trade Friday.The firm will now pay up to 116 yuan per share as opposed to the previous cap of 95 million yuan apiece previously.The company's board approved a share repurchase program in December to buy back between 20 million yuan and 40 million yuan worth of stocks.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","LU2328871848.SGD","09995","LU1969619763.USD","BK1161","BK1574"],"gpt_icon":0},{"id":"1194056253","title":"Stock Track | REMEGEN Soars 5.09% Intraday on AbbVie Licensing Deal for RC148","url":"https://stock-news.laohu8.com/highlight/detail?id=1194056253","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194056253?lang=en_us&edition=fundamental","pubTime":"2026-01-16 09:44","pubTimestamp":1768527886,"startTime":"0","endTime":"0","summary":"REMEGEN's stock surged 5.09% during the intraday session on Friday, driven by investor optimism following the announcement of an exclusive licensing agreement with AbbVie for RC148, a PD-1/VEGF...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09995"],"gpt_icon":0},{"id":"1149591971","title":"HK Market Daily: PBOC Cuts Key Rates by 25bps; State Grid Plans 4 Trillion Yuan \"16th Five-Year\" Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=1149591971","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149591971?lang=en_us&edition=fundamental","pubTime":"2026-01-16 08:05","pubTimestamp":1768521907,"startTime":"0","endTime":"0","summary":"The People's Bank of China announced that, effective January 19, it will lower the interest rates for relending and rediscount facilities by 0.25 percentage points. This move aims to enhance the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"531ba096f5502f39f4937c4f27f3448f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03993","ZFmain","LU2213484517.USD","IE0032431581.USD","603993","CKHUY","BK1592","TNmain","BK1583","BK1190","BK1116","LU0164880469.USD","UBmain","BK4574","BK4555","BK4548","BK1161","BK1151","02579","ZTmain","ZNmain","BK1500","LU0072462343.USD","NIO","BK1587","BK4526","LU2328871848.SGD","02190","688331","LU0052750758.USD","06936","BK1521","BK4532","09995","02465","BK4504","BK4534","BK4581","00001","LU1880383440.USD","09866","BK1594","BK4588","ZBmain","NIO.SI","BK1230","BK4509","BK1569","BK4505","LU1481107354.HKD","603906","LU1880383366.USD","BK1574","300919","002352","LU0149721374.USD","LU1969619763.USD","LU0320764599.SGD","LU1048588211.SGD","BK1601","BK4099","LU0708995583.HKD","BK1110","LU1571399168.USD","BK1100","EVS.SI","BK4585","BK4531"],"gpt_icon":1},{"id":"2603393309","title":"Assessing RemeGen (SEHK:9995) Valuation After AbbVie RC148 Licensing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2603393309","media":"Simply Wall St.","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603393309?lang=en_us&edition=fundamental","pubTime":"2026-01-16 01:27","pubTimestamp":1768498034,"startTime":"0","endTime":"0","summary":"Why AbbVie’s RC148 licensing deal matters for RemeGen\nRemeGen (SEHK:9995) moved into focus after AbbVie signed an exclusive licensing agreement for RC148, a PD-1/VEGF bispecific antibody. The deal grants AbbVie rights outside Greater China and secures sizeable upfront, milestone and royalty economics for RemeGen.\nSee our latest analysis for RemeGen.\nRemeGen’s share price has responded sharply to the AbbVie announcement, with a 23.53% 1 month share price return and a very large 1 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/assessing-remegen-sehk9995-valuation-after-abbvie-rc148-lice","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/assessing-remegen-sehk9995-valuation-after-abbvie-rc148-lice","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BFTCPJ56.SGD","LU0820561818.USD","LU2237443465.HKD","IE00B42XCP33.USD","IE00BJT1NW94.SGD","LU0689472784.USD","LU0689626769.HKD","IE0009355771.USD","LU0417517546.SGD","LU1061106388.HKD","LU0234572021.USD","LU0320765646.SGD","LU0738911758.USD","IE00B2B36J28.USD","LU2023251221.USD","LU0256863811.USD","LU0456855351.SGD","LU0128525929.USD","LU0882574055.USD","LU1244550577.SGD","LU0029864427.USD","LU0661504455.SGD","IE00BVYPNW00.USD","BK4581","DCF","LU0965509283.SGD","LU2237443895.HKD","ABBV","IE00BDGV0183.EUR","LU0124676726.USD","LU1718418525.SGD","LU1929549753.HKD","LU1037948897.HKD","LU0211328371.USD","LU1023059063.AUD","LU0289739699.SGD","LU0158827948.USD","IE00BSNM7G36.USD","LU0708994859.HKD","LU1244550494.USD","LU1839511570.USD","LU2129689431.USD","BK4534","09995","LU2089283258.USD","LU2237443622.USD","LU2468319806.SGD","LU0432979614.USD","LU0965509010.AUD","LU1291159041.SGD"],"gpt_icon":0},{"id":"1169098864","title":"Huaxi Securities Maintains \"Overweight\" Rating on REMEGEN (09995) as RC148 Bispecific Antibody Goes Global in $5.6 Billion Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1169098864","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169098864?lang=en_us&edition=fundamental","pubTime":"2026-01-15 09:26","pubTimestamp":1768440408,"startTime":"0","endTime":"0","summary":"Huaxi Securities has released a research report maintaining an \"Overweight\" rating on REMEGEN (09995). The brokerage firm highlights the company's robust independent R&D capabilities, steady growth...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","LU1064130708.USD","BK1583","LU1969619763.USD","688331","BK1574","LU2148510915.USD","002926","LU1064131003.USD","BK0276","LU2328871848.SGD","LU2488822045.USD","BK0239","BK1161"],"gpt_icon":0},{"id":"1132249843","title":"Zhutong Hong Kong Stock Connect Active Trading | January 13","url":"https://stock-news.laohu8.com/highlight/detail?id=1132249843","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132249843?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:14","pubTimestamp":1768302845,"startTime":"0","endTime":"0","summary":"On January 13, 2026, Alibaba-W (09988), Tencent Holdings (00700), and Xiaomi Group-W (01810) ranked as the top three stocks by turnover value on the Shanghai-Hong Kong Stock Connect (Southbound),...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002562.SGD","LU0501845795.SGD","HK0000165453.HKD","LU1956131251.USD","LU0140636845.USD","LU1951186391.HKD","LU0588545490.SGD","LU1051769294.HKD","LU0106259558.USD","LU2023250504.SGD","LU0463099449.HKD","SG9999013353.USD","LU1439103000.SGD","LU2242644610.SGD","LU0441854154.USD","LU0823041008.USD","01810","IE00BPRC5H50.USD","00981","LU0214875030.USD","LU0985320562.USD","LU1003077747.HKD","LU0865486749.SGD","LU1769817096.USD","BK1152","LU0165289439.USD","LU0823039010.USD","LU0359201612.USD","LU0132412106.USD","BK1586","LU0149534421.HKD","BK4565","METmain","LU0531970944.HKD","LU0210533765.USD","BK1588","IE0001KFT4U8.USD","LU0348766576.USD","LU1880398471.USD","LU1226287875.USD","LU0588546209.SGD","BK4524","LU0043850808.USD","BK1584","SGXZ49509284.SGD","LU0254981946.USD","LU1023057109.AUD","LU1734074674.USD","LU0661504455.SGD","LU2462611646.USD","LU1282649810.SGD","002202","BK4502","LU0310800965.SGD","LU1807302812.USD","LU2097828474.EUR","09995","600938","BK1536","LU0231483743.USD","LU1655091459.SGD","IE0008368304.USD","LU0039217434.USD","BK1576","LU1831875114.USD","IE0009570106.USD","IE00BMPRXN33.USD","LU1044874839.SGD","LU1642822792.SGD","BK4554","LU0856984785.SGD","LU1008478684.HKD","LU0107464264.USD","BK1608","LU2097828714.EUR","LU0106959298.USD","LU1064131003.USD","LU1046422090.SGD","LU1196710195.USD","BK4533","LU2097829019.USD","LU0588545904.SGD","IE00BQXX3F31.USD","LU0315179316.USD","LU0572944931.SGD","LU0049853897.USD","BK4220","LU0449509016.USD","LU0823413587.USD","LU0128525689.USD","BK4581","LU1226287529.USD","LU0651946864.USD","02228","IE00BFMHRM44.USD","HK0000352382.USD","BK4526","IE00B067MR52.USD","LU0821914370.USD","LU1051768304.USD","LU1880383366.USD","LU0541501648.USD","LU0029874905.USD","LU0315178854.USD","LU0384037296.USD","LU0229945570.USD","LU1366334578.USD","WXXWY","LU0117841782.USD","LU1868837722.USD","600941","LU0326950275.SGD","LU0173614495.USD","LU0823040885.USD","BK4538","LU0572940350.SGD","LU0327786744.USD","LU1868837565.USD","BK1238","LU0084288322.USD","HTCD.SI","LU1316542783.SGD","LU0251144936.SGD","IE00BZ08YS42.EUR","LU0588545730.USD","SG9999015978.USD","LU0469268626.HKD","BK4505","IE00B0169L03.USD","LU1880398554.USD","BK4558","LU0737861699.HKD","LU0348783233.USD","LU0823426308.USD","LU1733274390.USD","BK1614","BK1517","LU0828238088.HKD","HK0000320264.USD","LU0541502299.USD","LU0314109678.HKD","HK0000306685.HKD","LU1282651048.USD","LU0348784397.USD","SG9999001689.USD","00941","LU0650527681.SGD","LU2125910849.SGD","LU0577902454.USD","LU0823426480.USD","LU2362540622.SGD","LU1804176565.USD","LU0054450605.USD","LU1718418525.SGD","SG9999000327.SGD","LU1481107354.HKD","LU0345776255.USD","BK1610","BK4531","IE00B3M56506.USD","LU0499858602.USD","IE0008368742.USD","BK1523","LU0918141887.USD","LU1725190679.HKD","LU0070217475.USD","LU0164880469.USD","LU0738912210.USD","HK0000320223.HKD","LU2106854487.HKD","LU0516423091.SGD","LU1568876251.USD","LU0164865239.USD","LU0417516571.SGD","LU0370786039.SGD","LU1282649067.USD","LU1568876335.HKD","IE00BMPRXR70.SGD","LU0823413660.USD","LU1196710864.SGD","LU1981816686.USD","BK0214","SGXZ51526630.SGD","LU0052750758.USD","LU0572939691.SGD","LU2449936058.SGD","LU0762542818.HKD","LU0561508036.HKD","SG9999014674.SGD","LU2097828557.USD","BK1205","LU0320764599.SGD","02208","LU0196878994.USD","LU0061477393.USD","LU0345769631.USD","LU2247934214.USD","LU0417516902.SGD","LU0348816934.USD","IE00BQXX3D17.EUR","02269","LU2362541513.USD","BK1501","LU0828237940.HKD","LU1282649141.HKD","LU2279701549.SGD","LU0738911758.USD","LU0127658192.USD","LU0348814723.USD","LU2476274308.USD","SG9999015945.SGD","BK1531","HK0000306701.USD","LU0211977185.USD","IE00BF5LJ272.USD","LU1868838027.USD","LU0786609619.USD","SGXZ81514606.USD","LU0192582467.USD","LU1235295612.USD","03690","LU0143863198.USD","LU1152091754.HKD","LU0235996351.USD","LU2362541273.HKD","LU0873338254.USD","LU0345775950.USD","LU0918141705.HKD","LU1044875133.USD","LU1224709979.USD","LU0011963245.USD","LU0048388663.USD","LU1634259557.SGD","LU0326948709.USD","LU0203345920.USD","LU0320764755.SGD","BK1618","LU0054237671.USD","LU0210527791.USD","LU2357305700.SGD","BK1574","LU2148510915.USD","BK1502","LU0640798160.USD","LU2039709279.SGD","BK1506","LU0431992006.USD","BK1163","LU1226287792.SGD","LU2778985437.USD","LU1251922891.USD","LU0531971595.HKD","LU0545039389.USD","LU2226246903.HKD","LU0261947096.USD","LU0164872284.USD","IE00B97KM107.HKD","BK4585","BK1249","LU0594300179.USD","IE0008368411.USD","LU0823038988.USD","LU1328277881.USD","LU0348767384.USD","00883","LU0607220059.USD","LU1969619763.USD","LU1810669033.SGD","LU0509642566.USD","LU0651947912.USD","IE00B0169N27.USD","SGXZ31699556.SGD","LU1522347837.USD","LU0594300419.USD","LU0516422440.USD","BK4548","LU0244354667.USD","SG9999001846.SGD","LU1242518931.SGD","LU2237443978.SGD","89988","LU1917777945.USD","IE00B031J352.USD","LU0328353924.USD","LU0823397103.USD","BK1521","LU0898667661.SGD","LU3063872942.SGD","LU0878004406.USD","LU1814569148.SGD","LU0293314216.USD","BK4579","LU0345769128.USD","81024","LU1675838814.USD","80883","BK4543","IE00B29SXG58.USD","LU0611395673.USD","LU1115378108.SGD","LU1769817179.HKD","LU0329678337.USD","LU2251237306.USD","LU1102505762.USD","LU0608807946.USD","XIACY","LU1242518857.USD","SG9999000459.SGD","LU1102505929.USD","IE00B8L5B284.USD","HBBD.SI","LU0175139822.USD","LU0862451753.SGD","BK4122","BK4588","LU0630378429.USD","09988","LU1235294995.USD","LU0211331839.USD","LU0516422366.SGD","LU1226288170.HKD","LU1548497426.USD","BK1591","SG9999018865.SGD","LU0882747503.HKD","LU0117844026.USD","LU0228367735.SGD","LU0642271901.SGD","LU2265009873.SGD","BK1095","LU0329678170.USD","LU1211504680.USD","LU0130103400.USD","LU0886674414.USD","LU1634259391.SGD","LU2051468812.USD","LU0868486357.SGD","LU0348723411.USD","09926","SG9999014898.SGD","LU0972618739.USD","SG9999000418.SGD","LU0737861772.HKD","LU2257852520.SGD","BK1161","LU0029875118.USD","LU0823397285.USD","LU0287142896.SGD","LU0577902611.USD","IE00B031HW06.USD","LU0049112450.USD","LU2008162690.USD","LU0259732245.USD","BK1615","LU1808992512.USD","LU0348783662.USD","LU0700851271.USD","LU0169518387.USD","LU0831093199.SGD","LU0080751232.USD","LU1201861165.SGD","LU0762541174.USD","LU1048484197.HKD","BK1583","LU0516422952.EUR","LU2097828805.USD","688981","LU2498475776.HKD","LU1785774172.SGD","LU0828237510.HKD","SGXZ81163826.USD","LU0791591158.USD","BK1516","LU1719994722.HKD","LU0502904849.HKD","LU0096374516.USD","LU0210526637.USD","LU0553294199.USD","LU1813983027.USD","LU0067412154.USD","LU0228659784.USD","HMTD.SI","LU0819123356.HKD","IE00B031HY20.USD","SG9999001093.SGD","HXXD.SI","LU1883866441.USD","LU0831103253.SGD","LU0683595622.HKD","LU1267930227.SGD","LU1794554557.SGD","SG9999007991.SGD","BK1589","LU0708995583.HKD","00700","LU1048596156.SGD","LU2293587155.HKD","TCEHY","81810","BK4535","LU1823568750.SGD","LU0130518102.USD","LU0871576103.HKD","LU1366334651.USD","KSTmain","IE0032834883.USD","LU2317271919.USD","IE00B0JY6N72.USD","LU0048597586.USD","LU1196710351.USD","LU1974910355.USD","LU0348788117.USD","IE00BGV7N243.SGD","BK1594","BK1604","LU0784639295.USD","HK0000352291.HKD","LU1504937902.USD","LU0320764243.SGD","LU0188438112.USD","LU0128522157.USD","BK4504","LU0593848301.USD","LU0605514214.HKD","LU0348805143.USD","BK1142","LU0359202008.SGD","LU2488822045.USD","SG9999014906.USD","LU0396098781.USD","SG9999001226.SGD","SG9999004220.SGD","LU0634319403.HKD","LU0143863784.USD","LU2237443895.HKD","BK4534","LU1720051017.SGD","SG9999003461.SGD","LU2328871848.SGD","LU2097828631.EUR","IE0008369823.USD","BK1607","LU1497733631.SGD","LU1497733557.USD","LU0516423174.USD","SGXZ90724238.SGD","IE0034224299.USD","LU0540923850.HKD","LU0791590937.USD","LU0878005551.USD","LU0456846285.SGD","LU0672654166.SGD","LU0633140560.USD","LU0047713382.USD","IE0032431581.USD","LU0455707207.USD","LU0819121731.USD","SG9999001069.SGD","LU0264606111.USD","LU0072913022.USD","LU0499858438.USD","LU0708995153.HKD","LU1733274473.HKD","LU0456827905.SGD","LU1993786604.SGD","SG9999006597.SGD","LU0051755006.USD","LU0589944569.HKD","688331","IE00B543WZ88.USD","LU0633140727.USD","BK1233","LU2125910500.SGD","IE0003851619.USD","IE00BZ08YT58.USD","LU1323998911.USD","BK4503","BK1590","LU1497734951.SGD","01024","BK1558","LU0488056044.USD","LU0880133367.SGD","SG9999001051.SGD","LU2045819591.USD","BABA","LU0197773160.USD","LU2237443382.USD","LU1770034418.SGD","LU0449515922.USD","HK0000252160.HKD","LU0052756011.USD","LU1960683339.HKD","SG9999014914.USD","LU1303224171.USD","BK4614","LU2237443465.HKD","LU2476274720.SGD","BK1528","IE00B5MMRT66.SGD","LU1152091168.USD","LU1880383440.USD","LU2148611432.USD","HK0000500386.USD","LU0608807433.USD","LU0890818403.SGD","LU0289960550.SGD","LU0348827113.USD","LU0128522744.USD","LU0648000940.SGD","BK1526","SG9999018857.SGD","LU1226288097.SGD","SG9999015952.SGD","LU0577902371.SGD","LU0414403682.SGD","GB00BDT5M118.USD","SG9999002463.SGD","LU0203347892.USD","LU0762540952.USD","LU1720051108.HKD","BK4587","LU0251143458.SGD","LU1720050803.USD","LU0197773673.USD","LU1688375341.USD","SG9999017495.SGD","LU0348735423.USD","LU1515016050.SGD","LU2237443549.SGD","LU1064130708.USD","LU0269904917.USD","LU0543330566.HKD","IE0003895053.USD","LU1226288253.USD","BK1141","LU2251237488.HKD","LU0543330483.HKD","LU0261950983.USD","LU2177674079.SGD","LU2133065610.SGD","IE00BQXX3C00.GBP","BK4607","IE0003795394.USD","BK4575","BK1546","LU1439102457.SGD","SG9999006514.SGD","LU0181495838.USD","LU0648948544.HKD","BK1617","LU0359201885.HKD","LU1046421795.USD","LU1961090484.USD","LU0072462343.USD","LU0630378692.HKD","LU0979878070.USD","LU0048580855.USD","HK0000914660.USD","IE00B8HQ1Z84.USD","MIUmain","LU2087589342.USD","LU0797268264.HKD","LU1105468828.SGD","LU0675040207.SGD","SG9999001903.USD","LU1770036033.HKD","SG9999002828.SGD","LU0949170772.SGD","LU1044876610.USD","LU0163747925.USD","LU1188198961.HKD","SG9999014880.SGD","BK1575","LU2399975544.HKD","BK4527","LU0307460666.USD","HK0000914686.HKD","LU2152927971.USD","LU0577902298.EUR","LU1224444064.USD","SG9999015986.USD","LU0149721374.USD","BK1513","LU1282651121.HKD","BK1193","LU0577902538.SGD","IE00BZ08YR35.GBP","LU1328615791.USD","LU1629966141.USD","MPNGY","LU1282648689.USD","LU1048588211.SGD","IE0031814852.USD","SGXZ99366536.SGD","LU0348825331.USD","LU0477156797.USD","LU0417516738.SGD","BK1609","LU0106252389.USD","LU0456842615.SGD","LU2237443622.USD","LU0862451837.USD","HK0000252152.HKD"],"gpt_icon":1},{"id":"2603579409","title":"RemeGen Sells License to Anti-tumor Medicine RC148; Shares Jump 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603579409","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603579409?lang=en_us&edition=fundamental","pubTime":"2026-01-13 11:31","pubTimestamp":1768275073,"startTime":"0","endTime":"0","summary":"RemeGen (HKG:9995) sold the license to its RC148 medicine to AbbVie, under a deal with an upfront payment of $650 million, according to a Hong Kong bourse filing Monday.Shares of the biopharmaceutical","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","LU1969619763.USD","09995","BK1161","LU2328871848.SGD","BK1574"],"gpt_icon":0},{"id":"1193996945","title":"PD-1/VEGF Bispecific Antibody Deal Frenzy Returns? Remegen Inks $5.6 Billion Licensing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=1193996945","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193996945?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:11","pubTimestamp":1768270262,"startTime":"0","endTime":"0","summary":"AbbVie has secured the licensing rights for a bispecific antibody from Remegen. While AbbVie is embroiled in rumors of a $20 billion acquisition, another deal has been firmly sealed. On the evening...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","LU1064130708.USD","BK1583","LU1969619763.USD","688331","BK1574","LU2148510915.USD","LU1064131003.USD","LU2328871848.SGD","LU1169590202.USD","PD","LU1169589451.USD","LU2488822045.USD","BK0239","BK4023","BK1161"],"gpt_icon":0},{"id":"1105958376","title":"Stock Track | REMEGEN Soars 8.84% in Pre-Market on Exclusive Licensing Deal with AbbVie","url":"https://stock-news.laohu8.com/highlight/detail?id=1105958376","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105958376?lang=en_us&edition=fundamental","pubTime":"2026-01-13 09:30","pubTimestamp":1768267855,"startTime":"0","endTime":"0","summary":"REMEGEN's stock surged 8.84% in pre-market trading on Tuesday following the announcement of an exclusive licensing agreement with AbbVie for its novel bispecific antibody drug, RC148. The deal grants...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09995"],"gpt_icon":0},{"id":"1143833042","title":"Zhitoing HK Stock Morning Briefing | Four Ministries Issue Trial Work Measures on Government Investment Fund Layout and Guidance; Overnight China Concept Stock Index Rises 4.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143833042","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143833042?lang=en_us&edition=fundamental","pubTime":"2026-01-13 07:58","pubTimestamp":1768262305,"startTime":"0","endTime":"0","summary":"Four ministries, including the National Development and Reform Commission, have jointly issued the \"Trial Work Measures on Strengthening the Layout Planning and Investment Direction Guidance for...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","LU1497733557.USD","LU0572940350.SGD","BK1614","LU0051755006.USD","LU1634259557.SGD","BK1163","BK1161","LU0572939691.SGD","LU1497733631.SGD","LU0456827905.SGD","LU0210526637.USD","BK1231","BK1560","LU1634259391.SGD","BK1610","LU0264606111.USD","09988","BK1607","BABA","BK1117","LU1522347837.USD","BK1526","688331","BK1119","LU1497734951.SGD"],"gpt_icon":1},{"id":"1117696241","title":"REMEGEN (09995) Signs Exclusive Licensing Agreement with AbbVie for RC148","url":"https://stock-news.laohu8.com/highlight/detail?id=1117696241","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117696241?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:56","pubTimestamp":1768222577,"startTime":"0","endTime":"0","summary":"REMEGEN (09995) announced that on January 12, 2026, the company entered into an exclusive licensing agreement with AbbVie Group Holding Company (AbbVie) for RC148. RC148 is a novel bispecific...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","LU1064131003.USD","LU2148510915.USD","LU1969619763.USD","BK1574","BK0239","LU1064130708.USD","LU2488822045.USD","BK1161","LU2328871848.SGD","BK1583","688331"],"gpt_icon":0},{"id":"1111925554","title":"Hong Kong Stock Movement | REMEGEN (09995) Surges Over 11%, Institutions Indicate It's on Accelerated Commercialization Track","url":"https://stock-news.laohu8.com/highlight/detail?id=1111925554","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111925554?lang=en_us&edition=fundamental","pubTime":"2026-01-07 15:08","pubTimestamp":1767769707,"startTime":"0","endTime":"0","summary":"REMEGEN (09995) surged over 11%, with a gain of 11.02% at the time of writing to HKD 90.15, recording a turnover of HKD 577 million. According to the company's official social media account, it has...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU1064130708.USD","688331","LU2148510915.USD","LU2488822045.USD","BK1574","09995","LU1969619763.USD","BK1161","LU1064131003.USD","BK1583","LU2328871848.SGD"],"gpt_icon":0},{"id":"1176338166","title":"REMEGEN (09995) Had Not Commenced Share Repurchase as of December 31","url":"https://stock-news.laohu8.com/highlight/detail?id=1176338166","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176338166?lang=en_us&edition=fundamental","pubTime":"2026-01-05 19:32","pubTimestamp":1767612732,"startTime":"0","endTime":"0","summary":"As of December 31, 2025, REMEGEN (09995) announced that it had not yet initiated a share repurchase. The company intends to execute the buyback at an opportune time based on market conditions during...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1574","688331","LU1064130708.USD","09995","BK1161","LU2148510915.USD","BK0239","LU2328871848.SGD","LU1969619763.USD","BK1583","LU1064131003.USD"],"gpt_icon":0},{"id":"1155356550","title":"Stock Track | REMEGEN Soars 7.81% in Intraday Session as Vdisituzumab Nears Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1155356550","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155356550?lang=en_us&edition=fundamental","pubTime":"2026-01-05 14:56","pubTimestamp":1767596202,"startTime":"0","endTime":"0","summary":"REMEGEN (09995) surged 7.81% in the intraday session on Monday, driven by positive developments in its drug pipeline. The stock's rise follows the announcement that its drug Vdisituzumab is proposed...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09995"],"gpt_icon":0},{"id":"1131855541","title":"Hong Kong Stocks Movement | REMEGEN (09995) Surges Nearly 8% in Afternoon, Vdisituzumab New Indication Proposed for Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1131855541","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131855541?lang=en_us&edition=fundamental","pubTime":"2026-01-05 14:54","pubTimestamp":1767596062,"startTime":"0","endTime":"0","summary":"REMEGEN (09995) rose nearly 8% in the afternoon session. As of the time of writing, the stock was up 7.67%, trading at HKD 79.3, with a turnover of HKD 405 million. On the news front, as of December...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","BK0239","LU2328871848.SGD","LU1064131003.USD","BK1583","LU1969619763.USD","LU2148510915.USD","BK1574","LU1064130708.USD","LU2488822045.USD","688331","BK1161"],"gpt_icon":0},{"id":"2600090371","title":"RemeGen Co., Ltd.'s (HKG:9995) Intrinsic Value Is Potentially 38% Above Its Share Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2600090371","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600090371?lang=en_us&edition=fundamental","pubTime":"2026-01-03 08:03","pubTimestamp":1767398593,"startTime":"0","endTime":"0","summary":"Key Insights The projected fair value for RemeGen is HK$102 based on 2 Stage Free Cash Flow to Equity RemeGen is...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-co-ltds-hkg9995-intrinsic-value-is-potentially-38-ab","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-co-ltds-hkg9995-intrinsic-value-is-potentially-38-ab","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK1161","BK1574","LU2328871848.SGD","FCF","BK1583","LU1969619763.USD","DCF","BK4100","TV","09995"],"gpt_icon":0},{"id":"1105874842","title":"HK Stock Movement | REMEGEN (09995) Rises Over 3% as Self-Developed RC148 Achieves Dual-Path Breakthrough; Institutions Bullish on Clinical Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1105874842","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105874842?lang=en_us&edition=fundamental","pubTime":"2025-12-23 10:06","pubTimestamp":1766455574,"startTime":"0","endTime":"0","summary":"REMEGEN (09995) surged over 3%, reaching HK$78.8 by the time of writing, with a trading volume of HK$98.38 million. According to a research report, the company's self-developed PD-1/VEGF bispecific...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2148510915.USD","LU1064131003.USD","LU1969619763.USD","688331","BK1583","09995","LU2488822045.USD","LU1064130708.USD","BK1161","BK0239","BK1574","LU2328871848.SGD"],"gpt_icon":0},{"id":"2592018831","title":"RemeGen (SEHK:9995): Assessing Valuation After Shanghai Health Care Index Inclusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2592018831","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592018831?lang=en_us&edition=fundamental","pubTime":"2025-12-18 22:13","pubTimestamp":1766067199,"startTime":"0","endTime":"0","summary":"RemeGen (SEHK:9995) has just been added to the Shanghai Stock Exchange Health Care Sector Index, a change that puts the biotech directly on the radar of sector trackers and index-linked funds.\nSee our latest analysis for RemeGen.\nThe latest index inclusion comes after a sharp run, with the year to date share price return of 468.99% and a 396.12% one year total shareholder return now giving way to softer short term momentum as traders reassess risk and future growth.\nIf RemeGen’s surge has you...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-assessing-valuation-after-shanghai-health-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-assessing-valuation-after-shanghai-health-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","DCF","LU1969619763.USD","LU2328871848.SGD","BK1574","09995","BK1161"],"gpt_icon":0},{"id":"2592990753","title":"Does RemeGen’s Index Debut on Shanghai’s Health Care Benchmark Reframe the Bull Case For RemeGen (SEHK:9995)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990753","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990753?lang=en_us&edition=fundamental","pubTime":"2025-12-17 15:14","pubTimestamp":1765955689,"startTime":"0","endTime":"0","summary":"In December 2025, RemeGen Co., Ltd was added to the Shanghai Stock Exchange Health Care Sector Index, marking its inclusion among China’s listed healthcare names tracked by this benchmark.\nThis index inclusion can increase RemeGen’s visibility to institutional investors that track or reference sector indices, potentially influencing how the company is positioned in healthcare-focused portfolios.\nWith this new index inclusion as a backdrop, we’ll examine how RemeGen’s expanding profile within...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/does-remegens-index-debut-on-shanghais-health-care-benchmark","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/does-remegens-index-debut-on-shanghais-health-care-benchmark","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4023","BK1574","LU2328871848.SGD","LU1969619763.USD","09995","AI","BK4587","BK1161","BK4528","BK4551","BK4585","BK4543","BK4588","BK1583"],"gpt_icon":0},{"id":"1173001511","title":"Remegen Co.,Ltd. (688331.SH) Plans to Repurchase Shares Worth 20-40 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1173001511","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173001511?lang=en_us&edition=fundamental","pubTime":"2025-12-15 17:36","pubTimestamp":1765791389,"startTime":"0","endTime":"0","summary":"Remegen Co.,Ltd. (688331.SH) announced its intention to repurchase shares worth 20 to 40 million yuan. The repurchase price will not exceed 95 yuan per share. The repurchased shares are expected to be used for employee stock ownership plans or equity incentives.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU1064130708.USD","LU2148510915.USD","LU2328871848.SGD","688331","LU2488822045.USD","LU1969619763.USD","BK1583","BK0239","BK1161","LU1064131003.USD","09995"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0333},{"period":"1month","weight":0.2619},{"period":"3month","weight":0.059},{"period":"6month","weight":0.3823},{"period":"1year","weight":6.7373},{"period":"ytd","weight":0.3583}],"compareEarnings":[{"period":"1week","weight":0.0234},{"period":"1month","weight":0.054},{"period":"3month","weight":0.0633},{"period":"6month","weight":0.0813},{"period":"1year","weight":0.3751},{"period":"ytd","weight":0.0474}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The Company focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly operates its businesses in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.07869},{"month":2,"riseRate":0.8,"avgChangeRate":0.209338},{"month":3,"riseRate":0.4,"avgChangeRate":-0.022811},{"month":4,"riseRate":0.8,"avgChangeRate":0.104301},{"month":5,"riseRate":0.4,"avgChangeRate":-0.023394},{"month":6,"riseRate":0.8,"avgChangeRate":0.127757},{"month":7,"riseRate":0.6,"avgChangeRate":-0.032319},{"month":8,"riseRate":0.4,"avgChangeRate":0.068611},{"month":9,"riseRate":0.6,"avgChangeRate":0.099222},{"month":10,"riseRate":0.4,"avgChangeRate":0.027845},{"month":11,"riseRate":1,"avgChangeRate":0.038747},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"REMEGEN","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"REMEGEN(09995),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest REMEGEN(09995) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"REMEGEN,09995,REMEGEN股票,REMEGEN股票老虎,REMEGEN股票老虎国际,REMEGEN行情,REMEGEN股票行情,REMEGEN股价,REMEGEN股市,REMEGEN股票价格,REMEGEN股票交易,REMEGEN股票购买,REMEGEN股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"REMEGEN(09995),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest REMEGEN(09995) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}